NCT00408785View on ClinicalTrials.gov

A Study Of BOTOX For The Treatment Of Glabellar Lines

PHASE3CompletedINTERVENTIONAL
Enrollment

256

Participants

Timeline

Start Date

November 1, 2006

Primary Completion Date

May 9, 2007

Study Completion Date

May 9, 2007

Conditions
Glabellar Lines
Interventions
DRUG

Botulinum Toxin Type A

botulinum toxin type A 100 units, human serum albumin 0.5 mg, sodium chloride 0.9 mg

DRUG

sodium chloride

sodium chloride 0.9 mg

Trial Locations (4)

100034

GSK Investigational Site, Beijing

100036

GSK Investigational Site, Beijing

100853

GSK Investigational Site, Beijing

200040

GSK Investigational Site, Shanghai

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY